failed_experiment.db
← Back to browse

Medicine› Neurology› Parkinson's Disease Mechanisms and Treatments

Parkinson's disease — Metabolic syndrome in LRRK2 and GBA genetic Parkinson's

Submitted 2026-10-22

Field: Medicine › NeurologyType: No effect foundArea: parkinson's diseaseTarget: Metabolic syndrome in LRRK2 and GBA genetic Parkinson'sStage: full study

Hypothesis

Metabolic syndrome components would shape the clinical picture of LRRK2- and GBA-associated Parkinson's disease and the prodromal burden in unaffected carriers.

What failed

Across 562 participants (idiopathic, LRRK2 and GBA Parkinson's, non-manifesting carriers and non-carrier controls), the number of metabolic syndrome components did not differ between Parkinson's groups (p = 0.101) or between carrier groups (p = 0.685).

Broken assumption

Metabolic syndrome modifies how genetic Parkinson's disease presents.

Why

Only isolated components differed — higher triglycerides and more prediabetes in LRRK2 carriers — and the authors conclude metabolic syndrome as a whole does not appear to modify the genetic Parkinson's phenotype.

From the published paper: Thaler et al. Scientific Reports, 2020. ↗CC BY

Research ideas from this failure

Unvetted lead — read the papers

New hypotheses this failure suggests, each with a crucial experiment, a rival explanation of the original result, and the papers it rests on. Written by AI from paper titles and abstracts found on OpenAlex (and Europe PMC, for life and health sciences).

Related failures (1)

Matched on shared genes, mechanisms and ways of failing as well as wording. Each shows why it matched — treat these as leads rather than verdicts.

Links in published research

Where this experiment's genes are known to matter outside its own research area, and the papers behind those links. Sources: Open Targets Platform and Europe PMC.